Physician profile
Moshin Bajwa
NPI 1497743462
$23,310.26
in general payments reported to CMS, 2019-2025
36 companies · $2,226 in 2025
The $2,226 reported for 2025 was more than what 78% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,402 · 2020: $9,545 · 2021: $418 · 2022: $959 · 2023: $1,368 · 2024: $1,393 · 2025: $2,226.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,894 · Education: $92.19.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,894.08 |
| Education | $92.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $12,930.75 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Electromed, INC. | $2,491.81 | 2019-2025 | Smartvest |
| Viiv Healthcare Company | $1,600.00 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $918.72 | 2019-2024 | Uptravi, Opsumit |
| Astrazeneca Pharmaceuticals Lp | $892.43 | 2019-2025 | Airsupra, Tezspire, Breztri |
| Mylan Specialty L.P. | $861.63 | 2019-2023 | Yupelri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $518.94 | 2019-2025 | Jascayd, Ofev |
| Genzyme Corporation | $508.66 | 2019-2025 | |
| Philips North America LLC | $367.60 | 2019-2025 | (Ak6) Vest Therapy, Vest Therapy Und, Home Pi Undivided |
| Genentech USA, INC. | $276.76 | 2019-2020 | |
| Inspire Medical Systems, INC. | $236.65 | 2023-2025 | Inspire |
| Insmed, INC. | $202.99 | 2024-2025 | Arikayce, Brinsupri |
| Grifols USA, LLC | $195.53 | 2019-2024 | Prolastin-C Liquid |
| United Therapeutics Corporation | $127.28 | 2019-2025 | Tyvaso, Tyvaso |
| Sunovion Pharmaceuticals INC. | $112.16 | 2019-2020 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $107.17 | 2020-2021 | |
| Pulmonx Corporation | $107.00 | 2023-2025 | Chartis Catheter, Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console |
| Bayer Healthcare Pharmaceuticals INC. | $95.75 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $93.50 | 2019-2024 | Dupixent |
| Amgen INC. | $91.31 | 2022-2024 | Tezspire, Tavneos |
| Sanofi-Aventis U.S. LLC | $78.99 | 2023 | |
| Biosense Webster, INC. | $67.90 | 2024 | Carto 3 |
| Viatris Specialty LLC | $56.41 | 2025 | Yupelri |
| Paratek Pharmaceuticals, INC. | $52.82 | 2022-2023 | Nuzyra |
| Novartis Pharmaceuticals Corporation | $38.71 | 2019 | |
| Merck Sharp & Dohme LLC | $37.99 | 2019-2020 | |
| Inogen, INC. | $34.37 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $32.48 | 2022-2023 | Xarelto |
| Jazz Pharmaceuticals INC. | $32.09 | 2023 | |
| Mallinckrodt Enterprises LLC | $29.25 | 2019 | |
| Ani Pharmaceuticals, INC. | $24.37 | 2024 | Purified Cortrophin Gel |
| Abbott Laboratories | $21.32 | 2022 | |
| Optinose US, INC. | $20.27 | 2019 | |
| Janssen Biotech, INC. | $19.60 | 2022 | |
| Gilead Sciences, INC. | $13.85 | 2021 | |
| Shionogi INC | $13.20 | 2024 | Fetroja |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Moshin Bajwa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.